
Haemonetics Corporation
Haemonetics Corporation (HAE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · HAE · as of Jun 8, 2026
Key Statistics
Explore Haemonetics Corporation Data
hae stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 21 · Buy rate: 52.4%
The HAE analyst consensus is Buy, based on ratings from 21 Wall Street analysts over the past 3 months. The average 12-month price target is $75.33, representing +3.98% upside from the current price of $72.45.
Competitors & Peers
hae competitorsStock Performance
Full HistoryAbout Haemonetics Corporation
Haemonetics Corporation a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma coll…
what is haemonetics corporation · hae stock overview · haemonetics corporation company profile · who is haemonetics corporation ceo · hae NYSE · haemonetics corporation headquarters · haemonetics corporation business segments
About Stock Overview & Key Data
Haemonetics Corporation (HAE) is a Healthcare company in the Medical - Instruments & Supplies industry, listed on NYSE since May 10, 1991. As of the latest trading session, HAE stock price is $72.45, with a market capitalization of $3.3B. The stock has returned +1.10% over the past 12 months and -9.63% year-to-date.
According to 21 Wall Street analysts, the consensus rating for Haemonetics Corporation stock is Buy, with an average 12-month price target of $75.33. In fiscal year 2026, Haemonetics Corporation reported revenue of $1.3B and net income of $97.3M. For detailed data — including Haemonetics Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Haemonetics Corporation (HAE) stock price is $72.45. The stock is traded on NYSE under the ticker symbol HAE. The 52-week range is $47.32 – $87.32.